Abstract 959P
Background
The efficacy of immune checkpoint inhibitors combined with antivascular agents has been demonstrated in a variety of solid tumors including HCC. Suvemcitug, selectively binds to and blocks VEGFA from binding to VEGFR1 and 2, thereby inhibiting its activities and preventing tumour angiogenesis and ultimately suppressing tumour growth and metastasis. Envafolimab is a humanized single-domain anti- PD-L1 antibody which is administered subcutaneously (SC). This study aims to assess the efficacy and safety of the combination of suvemcitug and envafolimab as second-line or later therapy in patients (pts) with advanced HCC.
Methods
This was an open-label, multi-cohort, multicenter, phase II trial conducted in China. In Cohort B, eligible pts had received at least one prior line of treatment for HCC and were treated with suvemcitug (2 mg/kg IV Q3W) plus envafolimab (300 mg SC Q3W) until disease progression or unacceptable toxicity was observed. The primary endpoint was objective response rate (ORR) assessed by investigator review using RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of overall response (DoR), progression-free survival (PFS) and safety.
Results
As of March 31,2023, a total of 20 patients were treated with envafolimab and suvemcitug. 80.0% pts (16/20) received one prior therapy and 40.0% pts (8/20) were prior treated with immunotherapy. After a median follow up of 7.4 (5.0, 9.3) months, in 18 efficacy-evaluable patients, the confirmed ORR was 11.1% (2/18), and the DCR was 72.2% (13/18). The median PFS was 4.3 (95% CI 1.4-8.1) months. The most common grade 3 or greater treatment-related adverse events were proteinuria (20.0%,4/20), hypertension (5%,1/20), platelet count decreased (5%, 1/20), blood bilirubin increased (5%, 1/20), γ-glutamyl transferase increased, oesophagitis (5%, 1/20),and oral ulcer (5%, 1/20). No treatment-related death was reported.
Conclusions
The use of envafolimab and suvemcitug did not result in increased safety concerns. Suvemcitug and envafolimab demonstrated antitumor activity and manageable safety profile in pts with prior treated HCC. Research Sponsor: Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Clinical trial identification
NCT05148195.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18